Cooper Companies Director Kurzius Buys $549,300 in Shares. Is the Eye Care Stock About to Rally?
The Cooper Companies (COO) director Lawrence Erik Kurzius bought 10,000 shares at $54.93 each, totaling $549,300. His total holdings now stand at 31,099 shares. The company reported $4.2B revenue and $570.3M net income over the past year. Kurzius also serves as CEO of McCormick & Co (MCK).
How this was made
The 30-second read
Why it matters
An insider purchase can be interpreted as a bullish signal, but the modest size limits market reaction.
Market read
Primary Form 4 filing; small‑scale insider buy provides limited trading impetus.
What to watch
Director also serves as CEO of McCormick, which could influence his liquidity needs.
Background
The Cooper Companies (COO) is a medical‑device firm with $4.2B revenue, operating CooperVision and CooperSurgical.
Ticker impact
Director Lawrence Kurzius purchased 10,000 shares for $549,300, increasing his stake to 31,099 shares.
likely modest upward pressure as traders price in the bullish signal
The purchase is a primary Form 4 filing, but the amount is relatively small for a $10B market cap.
Market effects
Eye‑care device sector may see slight positive sentiment from insider confidence.
Limited to U.S. investors; no broader regional effect.
Minimal global impact.
Counterpoint
The purchase size is modest; market may view it as routine rather than a strong catalyst.
Key entities
- CompanyThe Cooper Companies, Inc.
US‑listed medical‑device company (ticker COO).
- IndividualLawrence Erik Kurzius
Independent director and buyer of COO shares.
